MASSA, FEDERICO
 Distribuzione geografica
Continente #
EU - Europa 6.874
AS - Asia 1.518
NA - Nord America 1.297
SA - Sud America 130
AF - Africa 25
OC - Oceania 4
Totale 9.848
Nazione #
IT - Italia 6.659
US - Stati Uniti d'America 1.195
SG - Singapore 498
CN - Cina 330
VN - Vietnam 297
BD - Bangladesh 243
BR - Brasile 77
FR - Francia 55
HK - Hong Kong 55
CA - Canada 49
FI - Finlandia 31
GB - Regno Unito 30
DE - Germania 22
AR - Argentina 18
JM - Giamaica 17
MX - Messico 15
JP - Giappone 10
PK - Pakistan 10
ID - Indonesia 9
IE - Irlanda 9
IN - India 9
IQ - Iraq 9
NL - Olanda 9
CO - Colombia 8
EC - Ecuador 8
CL - Cile 7
UA - Ucraina 7
CH - Svizzera 6
ES - Italia 6
RU - Federazione Russa 6
TR - Turchia 6
TW - Taiwan 6
ZA - Sudafrica 6
AT - Austria 5
PH - Filippine 5
PL - Polonia 5
PS - Palestinian Territory 5
SV - El Salvador 5
TN - Tunisia 5
AU - Australia 4
KE - Kenya 4
SE - Svezia 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
HN - Honduras 3
MA - Marocco 3
MY - Malesia 3
NI - Nicaragua 3
RS - Serbia 3
UZ - Uzbekistan 3
BO - Bolivia 2
CR - Costa Rica 2
DK - Danimarca 2
GR - Grecia 2
GT - Guatemala 2
IL - Israele 2
JO - Giordania 2
OM - Oman 2
PE - Perù 2
PR - Porto Rico 2
PY - Paraguay 2
SA - Arabia Saudita 2
TH - Thailandia 2
UY - Uruguay 2
AZ - Azerbaigian 1
BB - Barbados 1
BE - Belgio 1
BH - Bahrain 1
BS - Bahamas 1
BZ - Belize 1
CI - Costa d'Avorio 1
CY - Cipro 1
DZ - Algeria 1
EG - Egitto 1
GA - Gabon 1
GD - Grenada 1
HR - Croazia 1
IS - Islanda 1
KH - Cambogia 1
KW - Kuwait 1
KZ - Kazakistan 1
LT - Lituania 1
MD - Moldavia 1
MT - Malta 1
NO - Norvegia 1
NP - Nepal 1
PT - Portogallo 1
RO - Romania 1
SI - Slovenia 1
SN - Senegal 1
TZ - Tanzania 1
ZW - Zimbabwe 1
Totale 9.848
Città #
Genoa 3.446
Genova 1.533
Vado Ligure 817
Rapallo 474
San Jose 267
Singapore 238
Ashburn 153
Ho Chi Minh City 105
Hanoi 69
Beijing 64
Hong Kong 53
New York 49
Santa Clara 44
Lauterbourg 43
Council Bluffs 40
Los Angeles 37
Bordighera 29
Rome 29
Helsinki 26
Milan 23
Frankfurt am Main 19
Buffalo 17
Chicago 16
Bologna 15
Boardman 14
Orem 14
Kingston 13
Montreal 13
St Louis 12
Naples 11
Palermo 11
Tokyo 10
Turin 10
Atlanta 9
Houston 9
Toronto 9
Bari 8
Brooklyn 8
Dallas 8
Haiphong 8
Phoenix 8
Pisa 8
São Paulo 8
City of London 7
Da Nang 7
Dublin 7
Mexico City 7
Hải Dương 6
London 6
Marseille 6
Memphis 6
Phủ Lý 6
Quito 6
San Francisco 6
Tampa 6
Brescia 5
Charlotte 5
Columbia 5
Denver 5
Florence 5
Johannesburg 5
Lappeenranta 5
Miami 5
Milwaukee 5
Savona 5
Seattle 5
Acalanes Ridge 4
Cardiff 4
Douglasville 4
Istanbul 4
Jakarta 4
Karachi 4
Pavia 4
Philadelphia 4
Poplar 4
Richmond 4
Santiago 4
Warsaw 4
Amsterdam 3
Baldwin Park 3
Belgrade 3
Belo Horizonte 3
Biên Hòa 3
Bogotá 3
Buenos Aires 3
Bắc Ninh 3
Bến Tre 3
Calgary 3
Erie 3
Ha Long 3
Kuala Lumpur 3
Lahore 3
Madrid 3
Managua 3
Manchester 3
Montgomery 3
Newark 3
Ninh Bình 3
Pasadena 3
Piscataway 3
Totale 8.042
Nome #
Spinocerebellar ataxia 17: full phenotype in a 41 CAG/CAA repeats carrier. 229
Added value of semiquantitative analysis of brain FDG-PET for the differentiation between MCI-Lewy bodies and MCI due to Alzheimer’s disease 191
Accuracy and generalization capability of an automatic method for the detection of typical brain hypometabolism in prodromal Alzheimer disease 190
Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers 182
Striatal dopamine transporter SPECT quantification: head-to-head comparison between two three-dimensional automatic tools 182
Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer's Disease 178
Metabolic correlates of reserve and resilience in MCI due to Alzheimer's Disease (AD) Rik Ossenkoppele 168
The fate of patients with REM sleep behavior disorder and Mild Cognitive Impairment 167
Serum neurofilament light chain rate of change in Alzheimer's disease: potentials applications and notes of caution 161
Brain Resources: How Semantic Cueing Works in Mild Cognitive Impairment due to Alzheimer’s Disease (MCI-AD) 160
Epilepsy in Neurodegenerative Dementias: A Clinical, Epidemiological, and EEG Study 155
Cerebrospinal fluid NPTX2 changes and relationship with regional brain metabolism metrics across mild cognitive impairment due to Alzheimer's disease 153
Neuroimaging findings and clinical trajectories of Lewy body disease in patients with MCI 152
Could arterial spin labelling perfusion imaging uncover the invisible in N-methyl-d-aspartate receptor encephalitis? 152
Clinical and MRI Predictors of Conversion From Mild Behavioural Impairment to Dementia 152
Cuneus/precuneus as a central hub for brain functional connectivity of mild cognitive impairment in idiopathic REM sleep behavior patients 150
How can we define a brain health chart? A narrative review and a proposal 145
Utility of quantitative EEG in early Lewy body disease 145
Limbic Network Derangement Mediates Unawareness of Apathy in Mild Cognitive Impairment due to Alzheimer’s Disease: Clues from [18F]FDG PET Voxel-Wise Analysis 144
Anatomical and neurochemical bases of theory of mind in de novo Parkinson's Disease 142
The Role of Hub and Spoke Regions in Theory of Mind in Early Alzheimer’s Disease and Frontotemporal Dementia 139
Bendamustine-rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy. 138
Brain metabolic correlates of persistent olfactory dysfunction after sars-cov2 infection 136
Cerebrospinal Fluid Biomarkers Profiling in Cerebral Amyloid Angiopathy and Relationship With Disease Phenotypes 135
Getting the high school diploma with only one hemisphere: a case report 134
A case series of parainfectious Guillain-Barré syndrome linked to influenza A (H1N1) virus infection 132
The role of anterior prefrontal cortex in prospective memory: an exploratory FDG-PET study in early Alzheimer's disease 130
Case Report: Post-COVID-19 Vaccine Recurrence of Guillain-Barré Syndrome Following an Antecedent Parainfectious COVID-19-Related GBS 128
FDG-PET and ASL MRI identify largely overlapping hypermetabolic and hyperperfusion changes in limbic autoimmune encephalitis 127
The Free and Cued Selective Reminding Test: Discriminative Values in a Naturalistic Cohort 125
Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a multicenter retrospective study 123
Tracking the progression of Alzheimer's disease: Insights from metabolic patterns of SOMI stages 121
Clinical and biological underpinnings of longitudinal atrophy pattern progression in Alzheimer's disease 121
Neuroimaging Findings in Mild Cognitive Impairment 120
REMeDio: a proof-of-concept neuroprotection study for prodromal synucleinopathies 118
Clinical and metabolic profiles in behavioural frontotemporal dementia: Impact of age at onset 116
Increased incidence of axonal Guillain-Barré syndrome in La Spezia area of Italy: A 13-year follow-up study 116
Importance of intensive and prolonged rehabilitative treatment on the Guillain-Barrè syndrome long-term outcome: a retrospective study 115
Clinical utility and research frontiers of neuroimaging in movement disorders 114
Investigating interleukin-8 in Alzheimer's disease: A comprehensive review 114
Stratification Tools for Disease-Modifying Trials in Prodromal Synucleinopathy 111
FDG PET Unveils the Course of Paraneoplastic Cerebellar Degeneration: A Semiquantitative Analysis 110
WHAT MAINTENANCE THERAPY TO PERFORM IN PATIENTS WITH ANTI-MAG NEUROPATHY AFTER THE FIRST CYCLE OF RITUXIMAB? A COMPARISON BETWEEN TWO REGIMENS 109
Reciprocal Incremental Value of 18F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimer's Disease and Inconclusive First Biomarker 109
Discrepancy Between Patient and Caregiver Estimate of Apathy Predicts Dementia in Patients with Amnestic Mild Cognitive Impairment 107
Different z-score cut-offs for striatal binding ratio (SBR) of DaT SPECT are needed to support the diagnosis of Parkinson’s Disease (PD) and dementia with Lewy bodies (DLB) 107
Dopaminergic and Serotonergic Degeneration and Cortical [18 F]Fluorodeoxyglucose Positron Emission Tomography in De Novo Parkinson's Disease 107
Neurological long-COVID in the outpatient clinic: Two subtypes, two courses 107
Sex differences in neuroimaging biomarkers in healthy subjects and dementia 105
Derivation and Validation of a Phenoconversion-Related Pattern in Idiopathic Rapid Eye Movement Behavior Disorder 103
Abnormal sweating and “skin flushing” as possible predictive factor for treatment related fluctuations in Guillain-Barré syndrome: a case series and a review of the literature 103
Compressed sensing (CS) MP2RAGE versus standard MPRAGE: A comparison of derived brain volume measurements 102
N-methyl-D-aspartate receptor antibody-related pathologies and pre-existent mental state disorders 101
A case of Huntington disease-like 2 in a patient of African ancestry: the everlasting support of clinical examination in the molecular era 99
Polysomnographic correlates of sleep disturbances in de novo, drug naïve Parkinson's Disease 99
Magnetic susceptibility components reveal different aspects of neurodegeneration in alpha-synucleinopathies 97
Metabolic and dopaminergic correlates of intellectual enrichment in de-novo Parkinson's disease patients 91
Intravenous immunoglobulin bridging to rituximab in NMDAR encephalitis patients non-responders to first-line treatments 90
Incident anti-LGI1 autoimmune encephalitis during dementia with Lewy bodies: when Occam razor is a double-edged sword 88
Alzheimer's disease (AD) co-pathology in dementia with Lewy bodies (DLB): implications in the disease modification era 86
Autoimmune encephalitis: what the radiologist needs to know 85
Anti-LGI1 encephalitis and Langerhans cell histiocytosis: two associated entities? A case report 85
The Role of Monoaminergic Tones and Brain Metabolism in Cognition in~de~novo Parkinson's Disease 82
Outcomes after single-cycle rituximab monotherapy in patients with anti-MAG polyneuropathy: A bi-center experience with an average follow-up of 11 years 82
Cognitive and Brain Metabolism Profiles of Mild Cognitive Impairment in Prodromal Alpha-Synucleinopathy 82
COVID-19-associated serum and cerebrospinal fluid cytokines in post- versus para-infectious SARS-CoV-2-related Guillain–Barré syndrome 81
Exploring the brain metabolic correlates of process-specific CSF biomarkers in patients with MCI due to Alzheimer's disease: preliminary data 79
Toward Quantitative Neurology: Sensors to Assess Motor Deficits in Dementia 77
Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer's disease 74
18F-FDG-PET/CT (FDG-PET) in Neurodegenerative Disease 73
[18F]FDG PET metabolic correlates of cerebrospinal fluid TAR DNA-binding protein 43 in prodromal Alzheimer's disease 72
Machine learning based analysis of FDG-PET image data for the diagnosis of neurodegenerative diseases 65
Abnormal electroencephalographic rhythms from quiet wakefulness to light sleep in Alzheimer's disease patients with mild cognitive impairment 64
Presynaptic Dopaminergic Imaging Characterizes Patients with REM Sleep Behavior Disorder Due to Synucleinopathy 62
Case 4: Parkinson’s Disease with Onset as Mild Cognitive Impairment (MCI) 61
Integrating cerebrospinal fluid and [18F]-fluorodeoxyglucose positron emission tomography to diagnose Alzheimer's disease and research its pathophysiological substrates 61
Validation of the REM behaviour disorder phenoconversion-related pattern in an independent cohort 60
Diagnostic and prognostic value of dual-point amyloid PET in Alzheimer’s disease (AD) mimickers 60
Clinical and diagnostic implications of Alzheimer’s disease copathology in Lewy body disease 57
Ma2 antibody-associated limbic encephalitis: The early etiology treatment may modify the disease clinical trajectory 56
CSF IL-6, GDF-15, GFAP and NfL levels in early Alzheimer disease: a pilot study 55
Rituximab retreatment guided by CD27+ B-cell count vs. clinical relapse in anti-MAG polyneuropathy: a cost-effective approach with lower cumulative doses 50
European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders 45
null 44
Clinical versus biomarker-based diagnosis of neurocognitive disorders – Authors' reply 43
Editorial: CSF and blood biomarkers in COVID-19 and other neuroinfectious diseases 42
null 41
Right posterior hypometabolism in Pisa syndrome of Parkinson's disease: A key to explain body schema perception deficit? 40
Progression trajectories from prodromal to overt synucleinopathies: a longitudinal, multicentric brain [18F]FDG-PET study 38
Neuropsychological and clinical variables associated with cognitive trajectories in patients with Alzheimer's disease 35
Uncovering Clinical and Functional Neuroimaging Characteristics of Overt Stage Phenotypes Within the α-Synucleinopathy Spectrum 35
European consensus for the diagnosis of MCI and mild dementia: Preparatory phase 34
Diagnostic performance of molecular imaging methods in predicting the progression from mild cognitive impairment to dementia: an updated systematic review 33
Relationship between default mode network and resting-state electroencephalographic alpha rhythms in cognitively unimpaired seniors and patients with dementia due to alzheimer’s disease 30
Frailty in early Alzheimer's disease: Complementary clinical value and prognostic significance in biomarker-defined mild cognitive impairment due to Alzheimer's disease 30
CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease 29
Clinical Pathways for Diagnosing Neurocognitive Disorders: Insights From Process Mining a Memory Clinic Cohort 27
MRI susceptibility map weighted imaging (SMWI) as a neurodegeneration biomarker in the prodromal to overt alpha-synucleinopathy continuum 26
The Many Faces of REM Sleep Behavior Disorder. Providing Evidence for a New Lexicon 25
Role of Blood P-Tau Isoforms (181, 217, 231) in Predicting Conversion from MCI to Dementia Due to Alzheimer’s Disease: A Review and Meta-Analysis 21
Totale 9.972
Categoria #
all - tutte 36.271
article - articoli 34.349
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.633
Totale 72.253


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022495 28 5 8 35 29 40 23 92 45 84 30 76
2022/2023561 40 60 8 51 70 70 7 49 85 22 84 15
2023/2024613 47 47 13 94 49 100 44 46 24 26 34 89
2024/20252.337 103 116 65 194 228 246 220 412 116 122 238 277
2025/20264.672 608 185 264 318 531 234 536 272 385 485 426 428
2026/2027306 306 0 0 0 0 0 0 0 0 0 0 0
Totale 10.151